Can we achieve a complete HIV cure in more patients?
VRC01 antibody can delay but not prevent viral rebound after interruption of early treatment
Long-acting NRTI shows promise for HIV treatment and PrEP
Stillbirth more frequent in women with HIV in UK and Ireland than in general population
US HIV funding decisions on PEPFAR in 2017 will have critical effect on ability to reach 90-90-90 goals
First protease inhibitor combination pill maintains viral suppression
Adolescents with HIV do better in more prosperous African countries, even with treatment
France’s next PrEP study aims to assess the wider impact of PrEP on the HIV epidemic
Dutch study finds out whether gay men prefer daily or on-demand PrEP
